Novartis this week announced the launch of the Greater Manchester (UK) Future of Health Challenge and named the start-up businesses selected to participate. The intensive 12-week program will include training, mentoring, and support from leaders in the health and technology space to create new clinical solutions for patients in Greater Manchester and beyond. Fifteen participants were selected from over 100 applicants who replied to the call for creative use of new technologies to solve some of Greater Manchester’s most pressing health problems. In addition to access to world-class support and expertise, participating start-up companies also have a chance to receive cloud space and additional expert support from Google Cloud for Startups. Developmental projects entering the program range from advanced visualization software and tools to help improve cognition, to home-based care systems that support elderly independent living and a remote thermometer which requires no contact with the patient. The program asked applicant health technology start-ups and entrepreneurs to submit ideas that could be beneficial to one or more of three focus areas as selected by local health leaders: • Solutions that improve the experience of those with Dementia and/or Frailty. • Solutions allowing primary care and outpatient services to be delivered in or near the home for patients. • Innovations to allow Digital Nudges to improve Prevention and Public Health. The program's fifteen participants are:
Fierce Females in the Life Science Space
March 29th 2024In this week’s episode, in recognition of international women’s month, Editor Miranda Schmalfuhs has compiled audio clips from interviews with female KOLs that she's been fortunate enough to speak with over this past month for content across a few of our brands.
FDA Approves Roche’s Alecensa as Adjuvant Treatment for ALK-Positive Early-Stage NSCLC
April 19th 2024Data from the Phase III ALINA trial show that Alecensa reduced the risk of disease recurrence or death by 76% vs. platinum-based chemotherapy in patients with completely resected IB to IIIA ALK-positive non–small cell lung cancer.